Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
| Date | Est. | Actual | |
|---|---|---|---|
| Feb 12, 2026 | -$0.13 | -$0.05 | Beat |
| Nov 13, 2025 | -$0.12 | -$0.05 | Beat |
| Sep 29, 2025 | -$0.07 | -$0.05 | Beat |
| May 13, 2025 | -$0.05 | -$0.04 | Beat |
| Feb 11, 2025 | -$0.08 | -$0.09 | Miss |
| Nov 13, 2024 | -$0.05 | -$0.08 | Miss |